Claris Bio secures $118 million to launch pivotal eye-drop trials next year
read at Endpoints ↗DealPositive
Claris Bio announced a financing round that raised $118 million to move its investigational eye‑drop therapy forward.
The capital will fund two pivotal Phase 3 studies slated to start next year, focusing on a blinding eye disease that currently has no approved drugs.
Alongside the funding, the company introduced a new chief executive officer and appointed a new chair of the board as part of its leadership refresh.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Claris collects $118M to take eye drop into pivotal testing next year”
read at Endpoints ↗87 words · retrieved Jul 28
comments(0)
5-min edit window · permanent after that